TherapeuticsMD (NASDAQ:TXMD) Shares Down 1.5% – What’s Next?

TherapeuticsMD, Inc. (NASDAQ:TXMD)’s stock price dropped 1.5% during mid-day trading on Wednesday . The stock traded as low as $1.91 and last traded at $1.94. 16,607 shares were traded during mid-day trading, a decline of 45% from the average daily volume of 30,226 shares. The stock had previously closed at $1.97.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of TherapeuticsMD in a research report on Thursday, July 2nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

TherapeuticsMD Price Performance

The stock has a market capitalization of $22.45 million, a PE ratio of 32.33 and a beta of 0.59. The stock’s fifty day moving average is $2.04 and its 200-day moving average is $2.13.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($6.12) by $6.13. TherapeuticsMD had a net margin of 5.34% and a return on equity of 0.32%. The company had revenue of $0.72 million during the quarter, compared to analysts’ expectations of $19.77 million.

Hedge Funds Weigh In On TherapeuticsMD

A number of large investors have recently bought and sold shares of TXMD. Citadel Advisors LLC grew its holdings in TherapeuticsMD by 125.5% in the third quarter. Citadel Advisors LLC now owns 34,273 shares of the company’s stock valued at $36,000 after purchasing an additional 19,073 shares during the period. Renaissance Technologies LLC raised its stake in shares of TherapeuticsMD by 171.8% during the 4th quarter. Renaissance Technologies LLC now owns 96,500 shares of the company’s stock worth $157,000 after buying an additional 61,000 shares during the period. Finally, Tejara Capital Ltd lifted its position in shares of TherapeuticsMD by 1.9% during the 4th quarter. Tejara Capital Ltd now owns 350,852 shares of the company’s stock valued at $572,000 after buying an additional 6,649 shares in the last quarter. Institutional investors and hedge funds own 30.74% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.